Eculizumab for a catastrophic relapse in NMOSD: case report

David Gorriz1, Francisco Carlos Pérez-Miralles2, Carlos Quintanilla-Bordás2

  • 1Neuroinmunology Unit, Neurology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. gorriz_dav@gva.es.

Summary

This case report highlights a patient with severe Neuromyelitis Optica Spectrum Disorder (NMOSD) who responded positively to eculizumab after conventional treatments failed. The study also discusses the role of soluble neurofilament light chain (sNfL) in NMOSD management.